Welcome to our dedicated page for INTENSITY THERAPEUTICS news (Ticker: INTS), a resource for investors and traders seeking the latest updates and insights on INTENSITY THERAPEUTICS stock.
Intensity Therapeutics, Inc. develops intratumoral cancer therapies using proprietary non-covalent drug-conjugation technology. Its lead investigational product candidate, INT230-6, is designed for direct injection into tumors and combines cisplatin, vinblastine sulfate, and the SHAO diffusion and cell-penetration enhancer to disperse cytotoxic agents within cancer cells.
Recurring company news covers INT230-6 clinical development, including the INVINCIBLE-4 study in early-stage operable triple negative breast cancer and the INVINCIBLE-3 study in selected soft tissue sarcoma subtypes. Updates also address financial results, cash resources, intellectual-property protection for the intratumoral technology platform, at-the-market financing activity, Nasdaq listing compliance, and capital-structure actions affecting the company’s common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.